File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Blockade of β1- and desensitization of β 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis

TitleBlockade of β1- and desensitization of β 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis
Authors
Issue Date2004
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar
Citation
European Journal Of Pharmacology, 2004, v. 485 n. 1-3, p. 227-234 How to Cite?
AbstractThe aim of the present study was to analyse the role of β 1- and β2-adrenoceptors in the catecholamine-induced myocardial remodeling, especially the interstitial fibrosis. Wistar rats were subjected to a 2-week chronic isoprenaline administration (30 μg/kg/h). Rats received a concomitant treatment with the selective β1- adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective β2-adrenoceptor agonist salbutamol (40 μg/kg/h) for 1 week to induce β2-adrenoceptor desensitization. The pretreatment with salbutamol induced a 59% down-regulation of left ventricular β2-adrenoceptors compared to control. The extent of the isoprenaline-induced left ventricular fibrosis was significantly reduced in both the bisoprolol and salbutamol groups compared with the control isoprenaline-treated group especially in the apical region (1.7±0.6% and 1.4±0.3% versus 6.0±1.3%, respectively, P<0.005). β 1-adrenoceptor blockade and β2-adrenoceptors down-regulation provided similar protection against isoprenaline-induced cardiac interstitial fibrosis suggesting that both β-adrenoceptors are involved in such cardiac remodeling process. © 2003 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/171314
ISSN
2015 Impact Factor: 2.73
2015 SCImago Journal Rankings: 1.115
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBrouri, Fen_US
dc.contributor.authorHanoun, Nen_US
dc.contributor.authorMediani, Oen_US
dc.contributor.authorSaurini, Fen_US
dc.contributor.authorHamon, Men_US
dc.contributor.authorVanhoutte, PMen_US
dc.contributor.authorLechat, Pen_US
dc.date.accessioned2012-10-30T06:13:20Z-
dc.date.available2012-10-30T06:13:20Z-
dc.date.issued2004en_US
dc.identifier.citationEuropean Journal Of Pharmacology, 2004, v. 485 n. 1-3, p. 227-234en_US
dc.identifier.issn0014-2999en_US
dc.identifier.urihttp://hdl.handle.net/10722/171314-
dc.description.abstractThe aim of the present study was to analyse the role of β 1- and β2-adrenoceptors in the catecholamine-induced myocardial remodeling, especially the interstitial fibrosis. Wistar rats were subjected to a 2-week chronic isoprenaline administration (30 μg/kg/h). Rats received a concomitant treatment with the selective β1- adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective β2-adrenoceptor agonist salbutamol (40 μg/kg/h) for 1 week to induce β2-adrenoceptor desensitization. The pretreatment with salbutamol induced a 59% down-regulation of left ventricular β2-adrenoceptors compared to control. The extent of the isoprenaline-induced left ventricular fibrosis was significantly reduced in both the bisoprolol and salbutamol groups compared with the control isoprenaline-treated group especially in the apical region (1.7±0.6% and 1.4±0.3% versus 6.0±1.3%, respectively, P<0.005). β 1-adrenoceptor blockade and β2-adrenoceptors down-regulation provided similar protection against isoprenaline-induced cardiac interstitial fibrosis suggesting that both β-adrenoceptors are involved in such cardiac remodeling process. © 2003 Elsevier B.V. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejpharen_US
dc.relation.ispartofEuropean Journal of Pharmacologyen_US
dc.subject.meshAdrenergic Beta-1 Receptor Agonistsen_US
dc.subject.meshAdrenergic Beta-1 Receptor Antagonistsen_US
dc.subject.meshAdrenergic Beta-2 Receptor Agonistsen_US
dc.subject.meshAdrenergic Beta-2 Receptor Antagonistsen_US
dc.subject.meshAlbuterol - Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFibrosisen_US
dc.subject.meshHeart Ventricles - Drug Effects - Metabolism - Pathologyen_US
dc.subject.meshIsoproterenol - Toxicityen_US
dc.subject.meshMaleen_US
dc.subject.meshMyocardium - Metabolism - Pathologyen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Wistaren_US
dc.subject.meshReceptors, Adrenergic, Beta-1 - Physiologyen_US
dc.subject.meshReceptors, Adrenergic, Beta-2 - Metabolism - Physiologyen_US
dc.subject.meshVentricular Remodeling - Drug Effects - Physiologyen_US
dc.titleBlockade of β1- and desensitization of β 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosisen_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ejphar.2003.11.063en_US
dc.identifier.pmid14757145-
dc.identifier.scopuseid_2-s2.0-1642497576en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1642497576&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume485en_US
dc.identifier.issue1-3en_US
dc.identifier.spage227en_US
dc.identifier.epage234en_US
dc.identifier.isiWOS:000188712500028-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridBrouri, F=6508024955en_US
dc.identifier.scopusauthoridHanoun, N=6701625227en_US
dc.identifier.scopusauthoridMediani, O=6507974261en_US
dc.identifier.scopusauthoridSaurini, F=7801420155en_US
dc.identifier.scopusauthoridHamon, M=35497512500en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.scopusauthoridLechat, P=7102784631en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats